GILEAD SCIENCES, INC.
CIK: 0000882095Latest portfolio: $1.9B · Q4 2025
Holdings
6
Total Value
$1.9B
New Positions
0
Closed Positions
3
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | RCUSARCUS BIOSCIENCES INC | 31,424,760 | $748.9M | 38.69% | — | |
| 2 | GLPGGALAPAGOS NV | 16,707,477 | $550.6M | 28.45% | — | |
| 3 | ACLXARCELLX INC | 6,720,803 | $438.2M | 22.64% | — | |
| 4 | ASMBASSEMBLY BIOSCIENCES INC | 4,505,391 | $153.2M | 7.92% | — | |
| 5 | KYTXKYVERNA THERAPEUTICS INC | 4,126,119 | $38.8M | 2.00% | — | |
| 6 | XLOXILIO THERAPEUTICS INC | 9,105,451 | $5.8M | 0.30% | — |
Quarterly Changes
Sector Breakdown
Healthcare100.0% ($7.488525506164382e+23T)
Filing History
Fund Information
GILEAD SCIENCES, INC. is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $1.9B across 6 holdings. The largest position is ARCUS BIOSCIENCES INC (RCUS), representing 38.7% of the portfolio. Compared to the previous quarter, the fund opened 0 new positions and closed 3 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.